Pharmacological vitreolysis

Details Pharmacological vitreolysis Pharmacological vitreolysis

2011-03-29

2011-03-29

Kim, Taeyoon (Department: 1651)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Hydrolases

C424S094100, C424S094630, C424S094600, C604S290000

Reexamination Certificate

active

07914783

ABSTRACT:
Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.

REFERENCES:
patent: 2624691 (1953-01-01), Loomis
patent: 3234106 (1966-02-01), Hink
patent: 3950513 (1976-04-01), Jensen
patent: 4462980 (1984-07-01), Diedrichsen et al.
patent: 4774087 (1988-09-01), Wu et al.
patent: 4820516 (1989-04-01), Sawyer et al.
patent: 5288485 (1994-02-01), Kikuta et al.
patent: 5288489 (1994-02-01), Reich et al.
patent: 5292509 (1994-03-01), Hageman
patent: 5304118 (1994-04-01), Trese et al.
patent: 5637299 (1997-06-01), McDonagh
patent: 5722428 (1998-03-01), Kaplan et al.
patent: 5866120 (1999-02-01), Karageozian et al.
patent: 6051698 (2000-04-01), Janjic et al.
patent: 6183692 (2001-02-01), Trese et al.
patent: 6207066 (2001-03-01), Trese et al.
patent: 6355243 (2002-03-01), Novokhatny
patent: 6462071 (2002-10-01), Castillejos
patent: 6585972 (2003-07-01), Peyman
patent: 6596725 (2003-07-01), Peterson et al.
patent: 6610292 (2003-08-01), Karageozian et al.
patent: 6733750 (2004-05-01), Peyman
patent: 6787135 (2004-09-01), Trese
patent: 2002/0042652 (2002-04-01), Peyman
patent: 2002/0139378 (2002-10-01), Trese et al.
patent: 2002/0192794 (2002-12-01), Dadd
patent: 2003/0012778 (2003-01-01), Zimmerman et al.
patent: 2003/0026798 (2003-02-01), Zimmerman
patent: 2003/0113313 (2003-06-01), Peyman
patent: 2003/0147877 (2003-08-01), Trese et al.
patent: 2003/0175263 (2003-09-01), Trese et al.
patent: 2004/0081643 (2004-04-01), Peyman
patent: 2005/0118158 (2005-06-01), Pakola
patent: 2006/0257391 (2006-11-01), Bartels
patent: 2007/0128182 (2007-06-01), Bartels
patent: 2007/0141043 (2007-06-01), Bartels
patent: 2008/0008698 (2008-01-01), Bartels
patent: 2008/0050356 (2008-02-01), Pakola
patent: 985498 (1965-03-01), None
patent: WO 98/52602 (1998-05-01), None
patent: WO-01/34797 (2001-05-01), None
patent: WO-02/50290 (2002-06-01), None
patent: WO 02/50290 (2002-06-01), None
patent: WO-02/102837 (2002-12-01), None
patent: WO-2004/045558 (2004-06-01), None
patent: WO-2004/052228 (2004-06-01), None
Collen. 2001. Revival of Plasmin as a Therapeutic Agent? Thromb Haemost ; 86: 731-2.
Seeber. 2009. While not preventable, glaucoma is treatable. http://www.woodwardnews.net/homepage/local—story—018090622.html/resources—printstory. p. 1-2.
Medical Appendix 2002. Macular degeneration. http://www.patscotland.org.uk/medical—appendices/M/MACULAR%20DEGENERATION.pdf. p. 1-6.
Glaucoma. 2009. http://www.mayoclinic.com/print/glaucoma/DS00283/METHOD=print&DSECTION=all. p. 1-14.
Wiman and Collen,“Molecular Mechanism of physiological fibrinolysis,”Nature272(6):549-550, 1978.
Wiman and Wallen, “The specific interaction between plasminogen and fibrin: A physiological role of the lysine binding site in plasminogen,”Thrombosis Research, 1:213-222, 1977.
Komorowicz, et al., “Fibrinolysis with Des-Kringle Derivatives of Plasmin and Its Modulation by Plasma Protease Inhibitors,”Biochemistry37:9112-9118, 1998.
Sigma Specification Sheet. 2008. (http://www.signaaldrich.com/catalog/search/SpecificationSheetPage/SIGMA/P1867?PrtPrv=1). p. 1.
U.S. Appl. No. 12/156,907, filed Jun. 5, 2008, Pakola.
U.S. Appl. No. 12/156,911, filed Jun. 5, 2008, Pakola.
Asami T, Terasaki H, Kachi S, Nakamura M, Yamamura K, Nabeshima T, and Miyake Y (2004) Ultrastructure of internal limiting membrane removed during plasmin-assisted vitrectomy from eyes with diabetic macular edema. Ophthalmology, 111, 231-237.
Azzolini C, D'Angelo A, Maestranzi G, Codenotti M, Della Valle PPM, and Brancato R (2005) Intrasurgical plasmin enzyme in diabetic macular edema. Am J Ophthalmol, 139, 949-950.
Azzolini C, D'Angelo A, Maestranzi G, Codenotti M, Della VP, Prati M, and Brancato R (2004) Intrasurgical plasmin enzyme in diabetic macular edema. Am J Ophthalmol, 138, 560-566.
Bhisitkul RB (2001) Anticipation for enzymatic vitreolysis. Br J Ophthalmol, 85, 1-2.
Bishop PN (2000) Structural macromolecules and supramolecular organisation of the vitreous gel. Prog Retin Eye Res, 19, 323-344.
Chen W, Huang X, Ma XW, Mo W, Wang WJ, and Song HY (2008) Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator. Eye, 22, 300-307.
Chow et al. “Successful Closure of Traumatic Macular Holes” The Journal of Retinal and Vitreous Diseases, vol. 19, No. 5, 1999 (405-409).
Chow, et al., “Successful Closure of Traumatic Macular Holes”, Retina, 19(5):405-409 (1999).
Collen, D. “Revival of Plasmin as a Therapeutic Agent?” Thromb Haemost 2001; 86: 731-2.
Foos, Robert Y. “Vitreoretinal juncture; topographical variations” Investigative Opthalmology, Oct. 1972, vol. 11, No. 10, (801-808).
Gandorfer A (2008) Experimental evaluation of microplasmin—an alternative to vital dyes. Dev Ophthalmol, 42, 153-159.
Gandorfer A and Kampik A (2005) Intrasurgical plasmin enzyme in diabetic macular edema. Am J Ophthalmol, 139, 949-950.
Goldberg GI, Strongin A, Collier IE, Genrich LT, and Marmer BL (1992) Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem, 267, 4583-4591.
Gonias, Steven and Figler, Nancy. “α2-Macroglobulin is the primary inhibitor of miniplasmin in vitro and in vivo in the mouse” Biochem. J. (1988) 255, 725-730.
Hara A (1994) Surface structure of rabbit and human retina after enzymatic separation of inner limiting membrane. Jpn J Ophthalmol, 38, 375-381.
Hermel M and Schrage NF (2007) Efficacy of plasmin enzymes and chondroitinase ABC in creating posterior vitreous separation in the pig: a masked, placebo-controlled in vivo study. Graefes Arch Clin Exp Ophthalmol, 245, 399-406.
Jorge R, Oyamaguchi EK, Cardillo JA, Gobbi A, Laicine EM, and Haddad A (2003) Intravitreal injection of dispase causes retinal hemorrhages in rabbit and human eyes. Curr Eye Res, 26, 107-112.
Joshi MM, Ciaccia S, Trese MT, and Capone A, Jr. (2006a) Posterior hyaloid contracture in pediatric vitreoretinopathies. Retina, 26, S38-S41.
Joshi MM, Drenser K, Hartzer M, Dailey W, Capone A, Jr., and Trese MT (2006b) Intraschisis cavity fluid composition in congenital X-linked retinoschisis. Retina, 26, S57-S60.
Khono et al. “Immunofluorescent Studies of Fibronectin and Laminin in the Human Eye” Investigate Opthalmology & Visual Science, vol. 28. Mar. 1987. (506-514).
Kim NJ, Yu HG, Yu YS, and Chung H (2004) Long-term effect of plasmin on the vitreolysis in rabbit eyes. Korean J Ophthalmol, 18, 35-40.
Laryukhina GM and Ziangirova GG (1977) Experimental enzymatic vitreolysis. Vestn Oftalmol (6) 77-79.
Li X, Shi X, and Fan J (2002) Posterior vitreous detachment with plasmin in the isolated human eye. Graefes Arch Clin Exp Ophthalmol, 240, 56-62.
Marder et al. “Plasmin Induces Local Thromolysis Without Causing Hemorrhage: A Comparison with Tissue Plasminogen Activator in the Rabbit” Thromb Haemost 2001; 86: 739-45.
Moser TL, Enghild JJ, Pizzo SV, and Stack MS (1993) The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. J Biol Chem, 268, 18917-18923.
Okajima K, Abe H, a

Affiliated with

Also associated with

Rating

Pharmacological vitreolysis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmacological vitreolysis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmacological vitreolysis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2719529